Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 418-423

  Dupuis, L Lee ^a,b,c,d   Seto, Winnie ^a,d   Teuffel, Oliver ^b   Gibson, Paul ^f   Schultz, Kirk R ^g   Doyle, John D ^b,e   Gassas, Adam ^b,e   Egeler, R Maarten ^b,c,e   Sung, Lillian ^b,c,d   Schechter, Tal ^b,c,d  

^a SickKids ^*  (Canada)

^b Division of Haematology/Oncology   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acute graft versus host disease; Area under the curve; Cyclosporine; Pediatrics; Pharmacokinetics

Indexed keywords

CYCLOSPORIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHILD; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; STEADY STATE; TREATMENT DURATION; VALIDATION STUDY;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84873702202     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.031     Document Type: Article

References (29)

1. Jacobsohn D.A. Acute graft-versus-host disease in children. Bone Marrow Transplant 2008, 41:215-221.
2. Punnett A., Sung L., Price V., et al. Achievement of target cyclosporine concentrations as a predictor of severe acute GvHD in children receiving cyclosporine and methotrexate prophylaxis. Ther Drug Monit 2007, 29:750-757.
3. Martin P., Bleyzac N., Souillet G., et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003, 32:881-887.
4. Kanda Y., Hyo R., Yamashita T., et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006, 81:838-844.
5. Ram R., Storer B., Mielcarek M., et al. Association between calcineurin inhibitor blood concentration and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:414-422.
6. Malard F., Szydlo R., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host-disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
7. Ruutu T., Niederwieser D., Gratwohl A., Apperley J.F. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997, 19:759-764.
8. Levy G., Thervet E., Lake J., Uchida K. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 2002, 73. S12-S18.
9. Nashan B., Cole E., Levy G., Thervet E. Clinical validation studies of Neoral C2 monitoring: A review. Transplantation 2002, 73:S3-S11.
10. Schrauder A., Saleh S., Sykora K.W., et al. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough. Pediatr Transplant 2009, 13:444-450.
11. Barkholt L., Remberger M., Bodegard H., et al. Cyclosporine A (CSA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 40:683-689.
12. Willemze A.J., Cremers S.C., Schoemaker R.C., et al. Ciclosporin kinetics in children after stem cell transplantation. Br J Clin Pharmacol 2008, 66:539-545.
13. Hendriks M.P., Blijlevens N.M., Schattenberg A.V., et al. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006, 38:521-525.
14. Kong D., Shuttleworth P., Bailey M., Grigg A. CsA 2-h concentration correlates best with area under the concentration-time curve after allo-SCT compared with trough CsA. Bone Marrow Transplant 2012, 47:54-59.
15. Balci Y., Tavil B., Karabulut E., et al. Cyclosporine level at the second hour in pediatric hematopoietic stem cell transplant patients. Exp Clin Transplant 2011, 5:329-335.
16. Furukawa T., Kurasaki-Ida T., Masuko M., et al. Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation. Int J Hematol 2010, 92:144-151.
17. Hadjibabaie M., Vazirian I., Iravani M., et al. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients. Ther Drug Monit 2011, 33:673-680.
18. Inoue Y., Saito T., Ogawa K., et al. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation. J Clin Pharm Ther 2011, 36:518-524.
19. Willemze A.J., Press R.R., Lankester A.C., et al. CsA exposure is associated with acute GVHD and relapse in children after SCT. Bone Marrow Transplant 2010, 45:1056-1061.
20. Sibbald C., Seto W., Taylor T., et al. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Ther Drug Monit 2008, 30:434-438.
21. Osowski C.L., Dix S.P., Lin L.S., et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Tranplantation 1996, 61:1268-1272.
22. Canafax D.M., Graves N.M., Hilligoss D.M., et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991, 51:1014-1018.
23. Muller R., Buttner P. A critical discussion of intraclass correlation coefficients. Stat Med 1994, 13:2465-2476.
24. Lee J., Ong C.N. Statistical evaluation of agreement between two methods for measuring a quantitative variable. Comput Biol Med 1989, 19:61-70.
25. Ting L.S., Partovi N., Levy R.D., et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy 2006, 26:1232-1240.
26. Gerard C., Bleyzac N., Girard P., et al. Links between cyclosporine exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model. Pharm Res 2011, 28:531-539.
27. Wilhelm A., de Graaf P., Veldkamp A., et al. Population pharmacokinetics of cyclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. Br J Clin Pharmacol 2012, 73:553-563.
28. Pape L., Froede K., Strehlau J., et al. Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr Transplant 2003, 7:302-304.
29. Qui F., He X.-J., Sun Y.-X., et al. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. Pharmacol Rep 2011, 63:815-825.